RxDoctor Payments Data

Lisa Thomas, MD

Hematology & Oncology · Dunmore, PANPI 1346239894

Payments from drug & device makers

$6,861in general payments, 2019–2025

Across 43 payments — averaging $159.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$3K
  • Seagen Inc.$2K
  • AstraZeneca$677
  • Varian Medical Systems, Inc.$480
  • Janssen Scientific Affairs, LLC$340
  • Astellas Pharma US Inc$215
  • plus $877 from 20 others

What the payments were for

  • Consulting fees$3,92557%
  • Speaking & faculty fees$1,39520%
  • Travel & lodging$2624%
  • Food & beverage$5718%
  • Education$70710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,861 in reported general payments places this provider in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,279,378
Medicare patients
958
Services billed
231,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib57$782,530
TasignaNilotinib Hcl19$374,131
ImbruvicaIbrutinib19$287,339
CabometyxCabozantinib S-Malate14$269,233
Lenalidomide23$266,280
CalquenceAcalabrutinib Maleate15$229,595
EliquisApixaban88$78,583
XareltoRivaroxaban72$71,866
Abiraterone Acetate27$34,135
Anastrozole336$8,616
Hydroxyurea59$1,941
Letrozole69$1,497
Hydrocortisone52$988
Warfarin Sodium78$773
Escitalopram Oxalate50$613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$52$861,114145 claims
NovartisTasigna$38$374,13119 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$16$287,33919 claims
Exelixis Inc.Cabometyx$200$269,23314 claims
AstraZenecaCalquence$677$229,59515 claims
Johnson & JohnsonXarelto$46$71,86672 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$340$34,13527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 682 hematology & oncology providers in Pennsylvania.

Other hematology & oncology in Dunmore

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →